Zealand Pharma stock suffered its two worst days on record. Here’s what’s next for the weight loss drugmaker

Zealand Pharma stock suffered its two worst days on record. Here’s what’s next for the weight loss drugmaker

Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink the company’s obesity strategy. But while the market’s enthusiasm for the drug has meaningfully cooled, investors are shifting focus to…

Read More